Avrobio, Inc. AVRO
We take great care to ensure that the data presented and summarized in this overview for AVROBIO, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AVRO
View allLatest Institutional Activity in AVRO
Top Purchases
Top Sells
About AVRO
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at AVRO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2024
|
Marc Schwabish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$4,000
$2.38 P/Share
|
|
Dec 04
2024
|
Alise Reicin Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,717
+6.17%
|
-
|
|
Dec 03
2024
|
Peter Mc Namara Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+19.79%
|
$7,000
$2.38 P/Share
|
|
Oct 22
2024
|
Timothy A Springer |
BUY
Open market or private purchase
|
Direct |
300,000
+6.82%
|
$9,900,000
$33.59 P/Share
|
|
Sep 26
2024
|
Timothy A Springer |
BUY
Open market or private purchase
|
Direct |
50,000
+0.33%
|
$1,450,000
$29.57 P/Share
|
|
Sep 24
2024
|
Timothy A Springer |
BUY
Other acquisition or disposition
|
Indirect |
186,134
+50.0%
|
-
|
|
Sep 24
2024
|
Timothy A Springer |
BUY
Other acquisition or disposition
|
Direct |
1,054,759
+21.97%
|
-
|
|
Sep 24
2024
|
Timothy A Springer |
SELL
Other acquisition or disposition
|
Indirect |
1,240,893
-80.0%
|
-
|
|
Jun 20
2024
|
Braden Michael Leonard |
BUY
Other acquisition or disposition
|
Direct |
33,333
+50.0%
|
-
|
|
Jun 20
2024
|
Braden Michael Leonard |
BUY
Other acquisition or disposition
|
Indirect |
400,355
+50.0%
|
-
|
|
Jun 20
2024
|
Stefan Vitorovic |
BUY
Grant, award, or other acquisition
|
Indirect |
1,028,674
+50.0%
|
-
|
|
Jun 20
2024
|
Timothy A Springer |
BUY
Grant, award, or other acquisition
|
Indirect |
1,551,116
+50.0%
|
-
|
|
Jun 20
2024
|
Timothy A Springer |
BUY
Grant, award, or other acquisition
|
Direct |
2,692,005
+50.0%
|
-
|
|
Jun 20
2024
|
Praveen P. Tipirneni |
BUY
Grant, award, or other acquisition
|
Direct |
3,037
+50.0%
|
-
|
|
Jun 20
2024
|
Terrance Mcguire |
BUY
Grant, award, or other acquisition
|
Indirect |
1,157,976
+50.0%
|
-
|
|
Jun 20
2024
|
Peter Mc Namara Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,688
+50.0%
|
-
|
|
Jun 20
2024
|
Marcella K. Ruddy Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,065
+50.0%
|
-
|
|
Jun 20
2024
|
Christian Cortis Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
126,368
+50.0%
|
-
|
|
Jun 20
2024
|
Alise Reicin Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
124,530
+50.0%
|
-
|
|
Jun 20
2024
|
Alise Reicin Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
166,580
+50.0%
|
-
|
Last 12 Months Summary
| Other acquisition or disposition | 1.67M shares |
|---|---|
| Open market or private purchase | 1.12M shares |
| Grant, award, or other acquisition | 6.9M shares |
| Exercise of conversion of derivative security | 149K shares |
| Other acquisition or disposition | 1.24M shares |
|---|---|
| Payment of exercise price or tax liability | 53.1K shares |